EBS Q1 2017 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q1 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$117M+13.5% YoY

Gross Profit

$50M43.2% margin

Operating Income

$15M12.8% margin

Net Income

$10M9.0% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

-22.9%

Cash Flow

Operating Cash Flow

$42M

Free Cash Flow

$21M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$952M

Total Liabilities

$341M

Stockholders' Equity

$610M

Cash & Equivalents

$270M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$103M	+13.5%
Gross Profit	$50M	$54M	-6.0%
Operating Income	$15M	$21M	-29.5%
Net Income	$10M	$4M	+162.7%